Background/Objectives: To assess the distribution of interleukin (IL)-1b, IL-6, tumour necrosis factor (TNF)-a and C-reactive protein (CRP) according to the different definitions of metabolically healthy obesity (MHO). Subjects/Methods: A total of 881 obese (body mass index (BMI) X30 kg/m 2 ) subjects derived from the population-based CoLaus Study participated in this study. MHO was defined using six sets of criteria including different combinations of waist, blood pressure, total high-density lipoprotein cholesterol or low-density lipoprotein -cholesterol, triglycerides, fasting glucose, homeostasis model, high-sensitivity CRP, and personal history of cardiovascular, respiratory or metabolic diseases. IL-1b, IL-6 and TNF-a were assessed by multiplexed flow cytometric assay. CRP was assessed by immunoassay. Results: On bivariate analysis some, but not all, definitions of MHO led to significantly lower levels of IL-6, TNF-a and CRP compared with non-MH obese subjects. Most of these differences became nonsignificant after multivariate analysis. An posteriori analysis showed a statistical power between 9 and 79%, depending on the inflammatory biomarker and MHO definition considered. Further increasing sample size to overweight þ obese individuals (BMIX25 kg/m 2 , n ¼ 2917) showed metabolically healthy status to be significantly associated with lower levels of CRP, while no association was found for IL-1b. Significantly lower IL-6 and TNF-a levels were also found with some but not all MHO definitions, the differences in IL-6 becoming nonsignificant after adjusting for abdominal obesity or percent body fat. Conclusions: MHO individuals present with decreased levels of CRP and, depending on MHO definition, also with decreased levels in IL-6 and TNF-a. Conversely, no association with IL-1b levels was found.
Introduction
Cytokines, such as interleukin (IL)-1b, IL-6, tumour necrosis factor-a (TNF-a) and C-reactive protein (CRP) are important inflammatory biomarkers. Several authors have suggested that metabolically healthy obesity (MHO) subjects present with lower inflammation levels (Karelis et al., 2005; Shin et al., 2006; Koster et al., 2010) and that this lower level contributes to their favourable metabolic profile. Still, there is currently no standard definition of MHO, and we have previously shown that the use of different diagnostic criteria for MHO leads to a considerable difference in prevalence levels (Velho et al., 2010) . Further, some MHO definition criteria consider inflammatory markers (Wildman et al., 2008) , thereby biasing the relationship between MHO and inflammation. Finally, it is currently unknown whether the decreased inflammatory status observed for some MHO definitions actually holds true for other definitions.
In this study, we assessed the levels of several inflammatory biomarkers: IL-1b, IL-6, TNF-a and CRP between metabolically healthy and metabolically unhealthy obese subjects, using different definitions of MHO. We also extended the analysis to overweight individuals because overweight has also been associated with increased inflammation when compared with normal weight.
Materials and methods

Recruitment
The CoLaus Study was approved by the Institutional Ethics Committee of the University of Lausanne. The CoLaus Study is a cross-sectional study aimed at assessing the prevalence and deciphering the molecular determinants of cardiovascular risk factors in the Caucasian population of Lausanne, Switzerland, a town of 117 161 inhabitants, of which 79 420 are of a Swiss nationality.
The sampling procedure of the CoLaus Study has been described previously (Firmann et al., 2008) . Briefly, the complete list of Lausanne inhabitants aged 35-75 years (n ¼ 56 694) was provided by the population registry of the city. A simple, non-stratified random sample of 35% of the overall population was drawn. The following inclusion criteria were applied: (a) written informed consent; (b) age 35-75 years; (c) willingness to take part in the examination and donate blood sample; (d) Caucasian origin, defined as being born in a selected number of countries (list available from the authors). The last inclusion criterion was chosen because of the genetic aspect of the study. Recruitment began in June 2003 and ended in May 2006. Participation rate was 41%.
All participants attended the outpatient clinic of the University Hospital of Lausanne in the morning after an overnight fast. Data were collected by trained field interviewers in a single visit lasting about 60 min.
Behavioural data
According to their smoking histories, participants were classified as never, current or former smokers. Personal medicines, including prescribed and self-prescribed drugs, were collected together with their main indications.
Physical activity was assessed by questions focusing on walking and other types of exercises in minutes per week. A participant was considered as physically active if he/she reported practicing at least 2 h of leisure-time physical activity per week.
Clinical data
Personal history of cardiovascular disease was assessed if the participant reported a self-reported diagnosis of coronary heart disease (angina, myocardial infarction, coronary revascularization), stroke or peripheral arterial disease.
Body weight and height were measured with participants standing without shoes in light indoor clothes. Body weight was measured in kilograms to the nearest 100 g using a Seca scale. Height was measured to the nearest 5 mm using a Seca gauge. Overweight was defined as a body mass index (BMI)X25 and o30 kg/m 2 and obesity was defined as a BMIX30 kg/m 2 .
Waist was measured with a non-stretchable tape over the unclothed abdomen at the navel. Two measures were made and the mean value (expressed in centimetres) was used for analyses. Abdominal obesity was considered for a waist 4102 cm for men and 488 cm for women.
Body composition was assessed by electrical bioelectrical impedance analysis using the Bodystat 1500 analyzer (Isle of Man, UK). This device has been validated against reference methods (Ghosh et al., 1997) and its results have been shown to be more accurate than those obtained using a dual frequency bioelectrical impedance analysis device (Simpson et al., 2001) . The coefficient of variation for repeated measurements of electrical impedance is 0.7% (Steiner et al., 2002) ; the reproducibility has been shown to be between 1 and 5% (Martin et al., 2001) , and its correlation with reference methods such as isotope dilution is between 0.855 (Martin et al., 2001) and 0.96 (Simpson et al., 2001) . Participants had to fast for at least 5 h, not engage into strenuous physical activity for the previous 12 h and abstain from consuming caffeine or alcohol-containing beverages 24 h before the analysis.
Blood pressure was measured three times on the left arm after at least 10 min rest in the seated position using a clinically validated automated oscillometric sphygmomanometer (Omron HEM-907, Matsusaka, Japan), with an appropriately sized cuff. The average of the last two readings was used for analyses.
Biological data
Venous blood samples (50 ml) were drawn in the fasting state. All measurements were conducted using a Modular P apparatus (Roche Diagnostics, Rotkreuz, Switzerland) by the Clinical Laboratory of the Centre Hospitalier Universitaire Vaudois. The following analytical procedures (with maximum inter-and intra-batch coefficients of variance) were used: (a) total cholesterol by CHOD-PAP (1.6-1.7%); (b) high-density lipoprotein cholesterol by CHOD-PAP þ PEG þ cyclodextrin (3.6-0.9%); (c) triglycerides by GPO-PAP (2.9-1.5%); and (d) glucose by glucose dehydrogenase (2.1-1.0%). Insulin was assessed by a solid-phase, two-site chemiluminescent immunometric assay (Diagnostic Products Corporation, Los Angeles, CA, USA) with a maximum intra-assay coefficient of variance of 13.7%. Low-density lipoprotein was calculated using the Friedewald's formula. Homeostasis model assessment was used to evaluate insulin resistance using the following formula: fasting serum insulin level Â fasting plasma glucose level/22.5 (Matthews et al., 1985) .
Venous blood samples (50 ml) were drawn in the fasting state and allowed to clot. Serum was preferred to plasma as it has been shown that different anticoagulants may affect absolute cytokine levels differently (Flower et al., 2000; Skeppholm et al., 2008) . High sensitive CRP was assessed by immunoassay and latex HS (IMMULITE 1000-High, Diagnostic Products Corporation) with maximum intraand inter-batch coefficients of variation of 1.3% and 4.6%, respectively. Serum samples were kept at À80 1C before the assessment of IL-1b, IL-6 and TNF-a, and sent in dry ice to the laboratory. Levels of these cytokines were measured using a multiplexed particle-based flow cytometric cytokine assay (Vignali, 2000) . This methodology yields cytokine concentrations that correlate well with those obtained by other methods such as enzyme-linked immunosorbent assay (Dupont et al., 2005) . Milliplex kits were purchased from Millipore (Zug, Switzerland). The procedures closely followed the manufacturer's instructions. The analysis was conducted using a conventional flow cytometer (FC500 MPL, BeckmanCoulter, Nyon, Switzerland). Lower limits of detection for IL-1b, IL-6 and TNF-a were 0.2 pg/ml. A good agreement between signal and cytokine was found within the assay range (R 2 X0.99). Intra-and inter-assay coefficients of variation were, respectively, 15 and 16.7% for IL-1b, 16.9 and 16.1% for IL-6 and, 12.5 and 13.5% for TNF-a.
For quality control, repeated measurements were conducted in 80 subjects randomly drawn from the initial sample. Spearman's rank correlations between duplicate measurements were 0.914, 0.961 and 0.891 for IL-1b, IL-6 and TNF-a, respectively (all Po0.001). Lin's correlation coefficients were 0.969, 0.971 and 0.945 and intra-class correlation coefficients were 0.970, 0.972 and 0.946 for IL-1b, IL-6 and TNF-a, respectively (all Po0.001), indicating a good reproducibility.
Determination of the prevalence of metabolically healthy obese individuals The diagnosis of MHO was obtained based on a BMIX30 kg/m 2 and six different sets of cardiometabolic abnormalities (Karelis et al., 2004; Meigs et al., 2006; AguilarSalinas et al., 2008; Wildman et al., 2008; Lynch et al., 2009) , as described in a previous paper (Velho et al., 2010) . As one definition of MHO includes CRP levels (Wildman et al., 2008) , analysis of CRP levels was not performed for this definition. The different MHO definitions are summarized in Table 1 .
Statistical analysis
Statistical analysis was conducted using SAS version 9.2. (SAS Inc., Cary, NC, USA). Variables were expressed as percentage or as mean ± standard deviation except for IL-1b, IL-6, TNF-a and CRP, which were expressed as median and interquartile range. Bivariate comparisons were performed using parametric (Student's t-test) or non-parametric (Mann-Whitney) tests, depending on whether the variable presented or not a normal distribution. Chi-square or Fisher's exact test were used to assess differences between proportions. As gender (Stowe et al., 2010) , leisure-time physical activity (Fischer et al., 2007) , smoking (Fröhlich et al., 2003) and antibiotic/anti-inflammatory drugs have been associated with cytokine levels, they were included in all multivariate models. Multivariate analysis was performed on dosable (above lower limits of detection) log-transformed values of IL-1b, IL-6, TNF-a and CRP, and the results were expressed as exponentiated-adjusted mean±standard error.
The associations between MHO components were analysed using Spearman's nonparametric correlation and stepwise linear regression analysis using log-transformed values of IL-1b, IL-6, TNF-a and CRP as dependent variables. As the number of subjects with MHO was relatively low, the main analysis was conducted pooling obese and overweight participants as suggested by others (Wildman et al., 2008) . Because of the large number of tests performed, statistical significance was considered for Po0.001. Power and sample size calculations were performed with Proc Power of SAS using current sample sizes and data (averages and standard errors for MHO and non-MHO) from the multivariate-adjusted models.
Results
Participants' characteristics
Of the initial 6188 participants, 963 were obese (BMIX30 kg/m 2 ) and 881 (91.5%, 449 men and 432 women, mean age 56.0±10.2 years) had data for all sets of metabolic abnormalities and were thus eligible for analysis. A further 2254 participants were overweight, of which 2053 (91.1%, 1023 men and 850 women, mean age 54.5±10.9 years) had data for all sets of metabolic abnormalities. Finally, 1562 participants (924 women, 638 men) presented with abdominal obesity and had data for all sets of metabolic abnormalities.
The clinical characteristics of MHO and non-MHO subjects are summarized in Table 2 . Overall, participants with MHO were less frequently men and presented with a lower frequency of abdominal obesity than non-MHO; MHO participants were also younger and had a lower body fat, irrespective of the definition used.
Inflammatory biomarkers and MHO
The results comparing metabolically healthy overweight or obese participants with their non-metabolically healthy counterparts are summarized in Table 3 (for IL-1b and IL-6) and Table 4 (for TNF-a and CRP). Metabolically healthy overweight or obese participants presented with lower levels of CRP for all definitions considered, and lower levels of IL-6 and TNF-a were also found for some definitions considered. Conversely, no consistent trend was found for IL-1b (Table 3) . Finally, after adjusting for abdominal obesity or % body fat, the differences in IL-6 were no longer significant (Table 5) , while TNF-a and CRP retained their significance (Table 6 ).
Restricting the analysis to obese (BMIX30 kg/m 2 ) participants led to similar findings. For some definitions of MHO, participants with MHO presented with significantly lower levels of inflammatory biomarkers, but for most MHO definitions the differences did not reach statistical significance (Supplementary Tables 1 and 2) , probably due to the small sample size available. Indeed, an a posteriori power analysis showed a statistical power to detect differences ranging between 9 and 79%, depending on inflammatory biomarkers and MHO definition (Supplementary Table 3 ). Further stratification according to gender (Supplementary  Tables 4-7) led to similar findings, that is, decreased levels of inflammatory biomarkers among MHO participants for some but not for all definitions of MHO.
Discussion
In agreement with previous studies (Shin et al., 2006; Koster et al., 2010) , lower IL-6 levels were found in MHO relative to non-MHO participants, but most differences were not (265) 41.5 50.3 ± 9.4 84.9 37.0 ± 0.3 Test (P-value) 13.6 (o0.001) 11.9 (o0.001) 15.8 (o0.001) 9.29 (o0.001) Yes, metabolically healthy obese; no, not MHO (metabolically healthy obesity). Results are expressed as percentage (gender and abdominal obesity), average±standard deviation (age), and gender-and age-adjusted average± standard error (body fat %).
[2]
Statistical analysis by w 2 (gender and abdominal obesity), Student's t-test (age) or general linear model (body fat %). As the definition of Meigs includes abdominal obesity as one of the criteria, the frequency of participants with abdominal obesity was not assessed. statistically significant, probably due to small sample sizes. Further extending the analysis to metabolically healthy overweight or obese subjects showed some significant differences, which became non-significant again after adjusting for abdominal obesity or % body fat. Overall, our data are in agreement with the results of previous studies (Park et al., 2005; Di Renzo et al., 2008) , which suggested that increased IL-6 is associated with increased body fat content. Hence, the lower IL-6 levels found for some MHO definitions appear to be associated with a decreased body fat content in MHO subjects using these definitions (Messier et al., 2010) and not to a specific effect in MHO on IL-6 levels.
In this study, lower TNF-a levels were found among MHO subjects, although not for all MHO definitions used. Again, our findings are partly in agreement with the literature (Koster et al., 2010) and may be related to differing body fat content according to the definition of MHO used (Messier et al., 2010) . Still, the differences in TNF-a levels among some MHO definitions remained significant after adjusting for waist or body fat percentage ( Table 6 ), suggesting that metabolic pathways other than differing fat content might intervene. Possible explanations include a differing secretion capacity of adipocytes or a higher dietary intake of antiinflammatory components (Basu et al., 2006; Galland, 2010) among MHO subjects. The ongoing follow-up of the CoLaus cohort includes a dietary assessment and will provide more information on this topic in a near future.
A question might arise whether the observed differences in inflammatory markers are actually clinically significant. For instance, using the definition of Wildman et al. (2008) , the unadjusted differences in IL-6 and TNF-a levels between MHO and non-MHO subjects were 0.3 pg/ml and 0.35 pg/ml, respectively, similar to the difference between patients with subclinical cardiovascular disease and healthy subjects (Cesari et al., 2003) . The difference in IL-6 levels between MHO and non-MHO subjects was also comparable to the difference found between incident coronary heart disease cases and healthy controls in the Reykjavik Study, but slightly lower than in the British Regional Heart Study (for a review, see Danesh et al., 2008) . Hence, it is likely that the differences observed between MHO and non-MHO subjects are of clinical importance.
To our knowledge, this is the first study to assess IL-1b levels among MHO individuals. Our results did not show any consistent association between metabolically healthy status and IL-1b levels. Depending on the MHO definition used, higher, similar or lower IL-1b levels were found among MHO subjects relative to their non-MHO counterparts, and these findings did not change when the analysis was extended to overweight subjects.
MHO participants had significantly lower CRP levels than non-MHO, irrespective of the MHO definition used. These findings are in agreement with the literature (Karelis et al., 2005; Shin et al., 2006; Koster et al., 2010) and the most likely explanation is the lower body fat content among MHO subjects, which would lead to a decreased production of IL-6 and thus CRP (Karelis et al., 2005) . Still, and contrary to what was reported in another study (Karelis et al., 2005) , the difference in CRP levels between MHO and non-MHO subjects retained its statistical significance after adjusting for abdominal obesity or % body fat in almost all MHO definitions (Table 6 ). Overall, our data suggest that the lower CRP levels found among MHO subjects might partly be related to differences in % body fat, but that other factors might also exert an effect. Whether these lower CRP levels also translate into a lower risk of developing cardiovascular disease among MHO subjects remains to be assessed.
The differing results regarding cytokine levels according to the MHO definition used are probably due to the fact that these definitions actually lead to different obese subjects being considered as metabolically (un)healthy. For instance, we have previously demonstrated that only 5% of all obese subjects were considered as MHO by all six definitions used (Velho et al., 2010) . As no consensus exists regarding the definition of MHO, it is thus understandable that the conclusions of the statistical analyses are also not unequivocal. Hence, and as suggested previously (Messier et al., general linear model on log-transformed values adjusting for gender, age (four groups), smoking (three groups), leisure-time physical activity (two groups) and anti-inflammatory/ antibiotic drugs (yes/no). As the Wildmann criteria include CRP levels, no statistical analysis was performed. 2010), it would be of interest to standardize the identification of MHO individuals in order to allow proper comparison between studies. Still, most results suggest a decreased inflammatory status (decreased CRP levels) among MHO subjects, while the association with the other inflammatory markers awaits further investigation.
The reasons for the lower inflammatory status among MHO subjects are not known in detail. Adipocytes can synthesise IL-1b, IL-6 and TNF-a (Coppack, 2001) , and it has been shown that the variability of the IL-6 gene is significantly associated with adiposity (Qi et al., 2007) . It has also been shown that subcutaneous adipose tissue releases IL-6, but not TNF-a, in vivo (Mohamed-Ali et al., 1997), that circulating TNF-a levels are higher in abdominal obesity compared with peripheral obesity (Tsigos et al., 1999) , and that obese adults without metabolic syndrome present with lower visceral and higher subcutaneous fat than obese adults with the metabolic syndrome (Koster et al., 2010) . Higher IL-6 and TNF-a have also been associated with increased insulin resistance (Abbatecola et al., 2004) , although this statement has been challenged (EscobarMorreale et al., 2003) . As all MHO definitions included in this study had at least one marker of glucose metabolism (hyperglycaemia or insulin resistance defined by homeostasis model assessment status), it is possible that the lower levels of inflammatory biomarkers among MHO subjects could actually be due to a selection bias, that is, due to the criteria used to define MHO (absence of hyperglycaemia or insulin resistance). Notwithstanding, the differences in IL-6 and TNF-a between MHO and non-MHO subjects varied according to the MHO definition used, indicating that this selection bias might not fully explain the lower levels of inflammatory biomarkers among MHO subjects. Further, no significant differences were found when using the MHO definition that included low CRP as a criterion (Wildman et al., 2008) . Another possible explanation for the differing results between MHO definitions could be due to the metabolic components used to define MHO. The associations between inflammatory markers are summarized in Supplementary Tables 8 and 9 , and indicate that some components are not associated with inflammatory markers. For instance, the definition of MHO according to Karelis et al. (2005) includes many components (high-density lipoprotein cholesterol and low-density lipoprotein cholesterol, homeostasis model assessment), which are not associated with inflammatory markers; this might explain the absence of difference in inflammatory markers between MHO and non-MHO subjects using the Karelis definition. Conversely, the MHO definition of Meigs includes many components (waist, systolic blood pressure, diastolic blood pressure), which are significantly associated with inflammatory markers, thus, explaining the differences between MHO and non-MHO subjects. Overall, our findings suggest that the lower levels of inflammatory biomarkers found among MHO subjects could be due to a lower or different fat mass distribution (higher subcutaneous and lower visceral; Messier et al., 2010) , a different genetic background or simply a selection bias (criteria used to define MHO). Nevertheless, further studies are needed to assess which of these hypotheses (and possibly others) are actually true. For instance, it would be of interest to know whether the distribution of MHO differs after Mendelian randomization of the IL-1b, IL-6, TNF-a or CRP genes, but, to our knowledge, no such study has been performed yet. This study has several limitations worth pointing out. The participation rate was low (41%), but similar to other epidemiological studies (Wolf et al., 1998) . Only data for Caucasians were available; hence, our findings may not apply to other ethnicities for which other BMI thresholds have been suggested (Deurenberg, 2001 ). Although it is rather unlikely that ethnicity might influence the relationship between MHO and inflammatory biomarkers, further studies are needed to better assess this issue. Finally, the ongoing follow-up of the entire CoLaus cohort will allow us to see whether MHO individuals retain their metabolically healthy status and lower inflammatory levels throughout life, and whether these lower levels of inflammatory biomarkers are associated with a lower risk of cardiovascular disease. In summary, our results indicate that metabolically healthy overweight or obese individuals present with decreased levels of CRP and, depending on MHO definition, also with decreased levels in IL-6 and TNF-a, while no association with IL-1b levels was found. The association of MHO with reduced IL-6 levels appears to relate to the lower % body fat of MHO subjects. Lower % body fat of MHO subjects may also contribute to their low CRP levels, but other mechanisms seem also contributing. Reduced lowgrade chronic inflammation might be an important characteristic of metabolically healthy overweight individuals.
Conflict of interest
DW is a full-time employee of GlaxoSmithKline (GSK), a pharmaceutical company. PV and GW received an unrestricted grant from GSK to build the CoLaus Study. The other authors declare no conflict of interest.
